statistiche ricercatore

Continente	#
NA - Nord America	834
AS - Asia	554
EU - Europa	373
SA - Sud America	83
Continente sconosciuto - Info sul continente non disponibili	20
AF - Africa	13
OC - Oceania	1
Totale	1.878

Nazione	#
US - Stati Uniti d'America	793
SG - Singapore	213
CN - Cina	133
IT - Italia	88
FI - Finlandia	87
BR - Brasile	73
BD - Bangladesh	58
HK - Hong Kong	57
DE - Germania	47
VN - Vietnam	33
UA - Ucraina	27
CA - Canada	26
GB - Regno Unito	25
PL - Polonia	22
FR - Francia	20
TR - Turchia	17
RU - Federazione Russa	16
IN - India	11
NL - Olanda	11
IE - Irlanda	10
MX - Messico	8
JP - Giappone	7
ZA - Sudafrica	6
CZ - Repubblica Ceca	5
AR - Argentina	4
ES - Italia	4
TW - Taiwan	4
PK - Pakistan	3
AT - Austria	2
AZ - Azerbaigian	2
CR - Costa Rica	2
DZ - Algeria	2
GE - Georgia	2
ID - Indonesia	2
IQ - Iraq	2
IR - Iran	2
LT - Lituania	2
MA - Marocco	2
NO - Norvegia	2
PY - Paraguay	2
VE - Venezuela	2
AU - Australia	1
BE - Belgio	1
BO - Bolivia	1
CH - Svizzera	1
EC - Ecuador	1
EG - Egitto	1
ET - Etiopia	1
GM - Gambi	1
HN - Honduras	1
IL - Israele	1
JM - Giamaica	1
JO - Giordania	1
KZ - Kazakistan	1
LV - Lettonia	1
MN - Mongolia	1
MY - Malesia	1
NP - Nepal	1
PA - Panama	1
PR - Porto Rico	1
SA - Arabia Saudita	1
SE - Svezia	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
UZ - Uzbekistan	1
Totale	1.858

Nome	#
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	357
COVID-19 impact on consecutive neurological patients admitted to the emergency department	265
Where SUNCT Contacts TN: A Case Report	182
Un caso peculiare di ipertensione secondaria	129
Un caso peculiare di ipertensione arteriosa secondaria.	122
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine	119
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study	119
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine	98
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor	91
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination	84
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab	68
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation	62
Photophobia and migraine outcome during treatment with galcanezumab	62
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients	60
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination	60
Totale	1.878

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	52	0	19	0	0	0	2	4	2	4	4	6	11
2022/2023	62	5	4	1	3	5	11	0	12	13	2	2	4
2023/2024	75	4	1	10	5	1	19	0	1	12	1	13	8
2024/2025	402	8	0	4	62	27	29	32	30	48	39	70	53
2025/2026	946	76	90	45	113	89	87	169	42	58	58	42	77
2026/2027	54	40	14	0	0	0	0	0	0	0	0	0	0
Totale													1.878